(VIANEWS) – The Market ended the session with BENEVOLENTAI (BAI.AS) rising 11.11% to €1.00 on Monday, after three successive sessions in a row of losses. AEX-Index slid 0.76% to €735.85, following the last session’s downward trend on what was a somewhat down trend trading session today.
BENEVOLENTAI’s last close was €0.90, 87.41% under its 52-week high of €7.15.
About BENEVOLENTAI
BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
Earnings Per Share
As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-1.57.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -152.53%.
Moving Average
BENEVOLENTAI’s value is way below its 50-day moving average of €1.68 and way under its 200-day moving average of €2.90.
More news about BENEVOLENTAI (BAI.AS).
